Azoles: Back to the future

Current Opinion in Infectious Diseases

Volumn 24, Issue SUPPL. 2, 2011, Pages

  Perfect, John R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aspergillosis; Candidemia; Fluconazole; Fusariosis; Phaeohyphomycosis; Posaconazole; Scedosporiosis; Triazoles; Voriconazole; Zygomycosis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANIDULAFUNGIN; BIOLOGICAL MARKER; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; PYRROLE DERIVATIVE; TRIAZOLE; VORICONAZOLE;

ASPERGILLOSIS; ASPERGILLUS; CANDIDEMIA; CANDIDIASIS; CRYPTOCOCCOSIS; DRUG MONITORING; ENDOPHTHALMITIS; FUSARIOSIS; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INVASIVE CANDIDIASIS; MYCOSIS; NONHUMAN; OPPORTUNISTIC INFECTION; PHAEOHYPHOMYCOSIS; PRACTICE GUIDELINE; PROPHYLAXIS; PSEUDALLESCHERIASIS; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ZYGOMYCOSIS;

EID: 79959815615     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/01.qco.0000399605.75891.fc     Document Type: Review

References (199)

1. Mohr J, Johnson M, Cooper T, et al. Current options in antifungal pharmacotherapy. Pharmacotherapy 2008; 28:614-645. (Pubitemid 351620030)
2. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intraabdominal candidiasis in high-risk surgical patients. Crit Care Med 1999; 27:1066-1072. (Pubitemid 29314312)
3. Garbino J, Lew DP, Romand JA, et al. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: A randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive Care Med 2002; 28:1708-1717. (Pubitemid 35435471)
4. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001; 233:542-548. (Pubitemid 32234953)
5. Marr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96:2055-2061.
6. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131:729-737. (Pubitemid 29531981)
7. Shorr AF, Chung K, Jackson WL, et al. Fluconazole prophylaxis in critically ill surgical patients: A meta-analysis. Crit Care Med 2005; 33:1928-1935; quiz 1936. (Pubitemid 41306511)
8. Glasmacher A, Prentice A, Gorschluter M, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21:4615-4626. (Pubitemid 46594036)
9. Playford EG, Webster AC, Sorrell TC, Craig JC. Antifungal agents for preventing fungal infections in nonneutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials. J Antimicrob Chemother 2006; 57:628-638.
10. Vardakas KZ, Samonis G, Michalopoulos A, et al. Antifungal prophylaxis with azoles in high-risk, surgical intensive care unit patients: A meta-analysis of randomized, placebo-controlled trials. Crit Care Med 2006; 34:1216-1224.
11. Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: A meta-analysis of randomised-controlled trials. Br J Haematol 2005; 131:22-28. (Pubitemid 43899704)
12. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis 2008; 46:327-360. (Pubitemid 351265310)
13. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335-347. (Pubitemid 46148776)
14. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-359. (Pubitemid 46148777)
15. Noxafil [package insert]. Kenilworth, New Jersey: Schering-Plough; 2009.
16. Sanchez-Ortega I, Patino B, Arnan M, et al. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation. Bone Marrow Transplant 2010; 46:733-739.
17. Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116:5111-5118.
18. Cordonnier C, Rovira M, Maertens J, et al. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 2010; 95:1762-1768.
19. Viscoli C. Antifungal prophylaxis and preemptive therapy. Drugs 2009; 69 (Suppl 1):75-78.
20. Zaragoza R, Peman J, Salavert M, et al. Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts? Ther Clin Risk Manag 2008; 4:1261-1280.
21. De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis: has the principle been proven? N Engl J Med 2007; 356:409-411. (Pubitemid 46148784)
22. Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole [abstract 2849]. Blood 2006; 108.
23. Chayakulkeeree M, Ghannoum MA, Perfect JR. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 2006; 25:215-229. (Pubitemid 43800540)
24. Imhof A, Balajee SA, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39:743-746. (Pubitemid 39180450)
25. Kobayashi K, Kami M, Murashige N, et al. Breakthrough zygomycosis during voriconazole treatment for invasive asprgillosis. Haematologica 2004; 89:ECR42.
26. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: A casecontrol observational study of 27 recent cases. J Infect Dis 2005; 191:1350-1360.
27. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350:950-952. (Pubitemid 38252550)
28. Mattner F, Weissbrodt H, Strueber M. Two case reports: fatal Absidia corymbifera pulmonary tract infection in the first postoperative phase of a lung transplant patient receiving voriconazole prophylaxis, and transient bronchial Absidia corymbifera colonization in a lung transplant patient. Scand J Infect Dis 2004; 36:312-314. (Pubitemid 38714188)
29. Oren I. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis 2005; 40:770-771. (Pubitemid 40381359)
30. Ritz N, Ammann RA, Aebischer CC, et al. Failure of voriconazole to cure disseminated zygomycosis in an immunocompromised child. Eur J Pediatr 2005; 164:231-235. (Pubitemid 40543793)
31. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39:584-587. (Pubitemid 39120940)
32. Vigouroux S, Morin O, Moreau P, et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: Attention required. Clin Infect Dis 2005; 40:e35-e37.
33. Lamaris GA, Ben-Ami R, Lewis RE, et al. Increased virulence of Zygomycetes organisms following exposure to voriconazole: A study involving fly and murine models of zygomycosis. J Infect Dis 2009; 199:1399-1406.
34. Ruping MJ, Vehreschild JJ, Cornely OA. Patients at high risk of invasive fungal infections: when and how to treat. Drugs 2008; 68:1941-1962.
35. Garey KW, Rege M, Pai MP, et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multiinstitutional study. Clin Infect Dis 2006; 43:25-31. (Pubitemid 43939072)
36. Gomez J, Garcia-Vazquez E, Espinosa C, et al. Nosocomial candidemia at a general hospital: prognostic factors and impact of early empiric treatment on outcome. Med Clin (Barc) 2010; 134:1-5.
37. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640-3645. (Pubitemid 41233011)
38. Nolla-Salas J, Sitges-Serra A, Leon-Gil C, et al. Candidemia in nonneutropenic critically ill patients: Analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med 1997; 23:23-30. (Pubitemid 27067892)
39. Patel GP, Simon D, Scheetz M, et al. The effect of time to antifungal therapy on mortality in Candidemia associated septic shock. Am J Ther 2009; 16:508-511.
40. Zilberberg MD, Kollef MH, Arnold H, et al. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: A retrospective cohort study. BMC Infect Dis 2010; 10:150.
41. Hope WW, Petraitis V, Petraitiene R, et al. The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) beta-d-glucan and consequences of delayed antifungal therapy. Antimicrob Agents Chemother 2010; 54: 4879-4886.
42. Ostrosky-Zeichner L, Kullberg BJ, Bow EJ, et al. Early treatment of candidemia in adults: A review. Med Mycol 2011; 49:113-120.
43. Takesue Y, Kakehashi M, Ohge H, et al. Combined assessment of beta-Dglucan and degree of candida colonization before starting empiric therapy for candidiasis in surgical patients. World J Surg 2004; 28:625-630. (Pubitemid 38802803)
44. Alam FF, Mustafa AS, Khan ZU. Comparative evaluation of (1, 3)-beta-Dglucan, mannan and antimannan antibodies, and Candida species-specific snPCR in patients with candidemia. BMC Infect Dis 2007; 7:103.
45. Digby J, Kalbfleisch J, Glenn A, et al. Serum glucan levels are not specific for presence of fungal infections in intensive care unit patients. Clin Diagn Lab Immunol 2003; 10:882-885. (Pubitemid 37129504)
46. Ellis M, Al-Ramadi B, Finkelman M, et al. Assessment of the clinical utility of serial beta-D-glucan concentrations in patients with persistent neutropenic fever. J Med Microbiol 2008; 57:287-295. (Pubitemid 351358531)
47. Senn L, Robinson JO, Schmidt S, et al. 1,3-Beta-D-glucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis 2008; 46:878-885. (Pubitemid 351417190)
48. Obayashi T, Yoshida M, Mori T, et al. Plasma (1->3)-beta-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes. Lancet 1995; 345:17-20.
49. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39:199-205. (Pubitemid 38971490)
50. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41:654-659. (Pubitemid 41170353)
51. Pickering JW, Sant HW, Bowles CA, et al. Evaluation of a (1->3)-beta-Dglucan assay for diagnosis of invasive fungal infections. J Clin Microbiol 2005; 43:5957-5962. (Pubitemid 43100644)
52. Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis 2007; 44:2-12. (Pubitemid 44968977)
53. Martini A, Gottin L, Menestrina N, et al. Procalcitonin levels in surgical patients at risk of candidemia. J Infect 2010; 60:425-430.
54. von Baum H, Ober JF, Wendt C, et al. Antibiotic-resistant bloodstream infections in hospitalized patients: specific risk factors in a high-risk population? Infection 2005; 33:320-326. (Pubitemid 41552007)
55. Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, et al. Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother 2010; 54:3149-3154.
56. Rodriguez D, Almirante B, Cuenca-Estrella M, et al. Predictors of candidaemia caused by nonalbicans Candida species: results of a population-based surveillance in Barcelona, Spain. Clin Microbiol Infect 2010; 16:1676-1682.
57. Charles PE, Castro C, Ruiz-Santana S, et al. Serum procalcitonin levels in critically ill patients colonized with Candida spp.: new clues for the early recognition of invasive candidiasis? Intensive Care Med 2009; 35:2146-2150.
58. Munoz P, Burillo A, Bouza E. Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit. Int J Antimicrob Agents 2000; 15:83-90. (Pubitemid 30347248)
59. Piarroux R, Grenouillet F, Balvay P, et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Crit Care Med 2004; 32:2443-2449. (Pubitemid 39648226)
60. Leon C, Ruiz-Santana S, Saavedra P, et al. A bedside scoring system (''Candida score'') for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006; 34:730-737.
61. Leon C, Ruiz-Santana S, Saavedra P, et al. Usefulness of the ''Candida score'' for discriminating between Candida colonization and invasive candidiasis in nonneutropenic critically ill patients: A prospective multicenter study. Crit Care Med 2009; 37:1624-1633.
62. Ostrosky-Zeichner L, Sable C, Sobel J, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007; 26:271-276. (Pubitemid 46572022)
63. Paphitou NI, Ostrosky-Zeichner L, Rex JH. Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: Approach to developing practical criteria for systematic use in antifungal prophylaxis trials. Med Mycol 2005; 43:235-243. (Pubitemid 40867497)
64. Sandrock C, Siddiqui J. The value of a risk model for early-onset candidemia. Crit Care 2009; 13:1005.
65. Shorr AF, Tabak YP, Johannes RS, et al. Candidemia on presentation to the hospital: development and validation of a risk score. Crit Care 2009; 13:R156.
66. Schuster MG, Edwards JE Jr, Sobel JD, et al. Empirical fluconazole versus placebo for intensive care unit patients: A randomized trial. Ann Intern Med 2008; 149:83-90. (Pubitemid 352008596)
67. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis 2009; 48:503-535.
68. Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the infectious diseases society of America. Clin Infect Dis 2008; 46:1801-1812.
69. Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. Clin Infect Dis 2005; 41:1217-1223. (Pubitemid 41532662)
70. Kauffman CA, Bustamante B, Chapman SW, Pappas PG. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the infectious diseases society of America. Clin Infect Dis 2007; 45:1255-1265. (Pubitemid 351411897)
71. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 2010; 50:291-322.
72. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the infectious diseases society of America. Clin Infect Dis 2007; 45:807-825. (Pubitemid 47580372)
73. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994; 331:1325-1330. (Pubitemid 24347001)
74. Anaissie EJ, Darouiche RO, Abi-Said D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996; 23:964-972. (Pubitemid 26367478)
75. Phillips P, Shafran S, Garber G, et al. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in nonneutropenic patients. Canadian Candidemia Study Group. Eur J Clin Microbiol Infect Dis 1997; 16:337-345. (Pubitemid 27271820)
76. Kontoyiannis DP, Bodey GP, Mantzoros CS. Fluconazole vs. amphotericin B for the management of candidaemia in adults: A meta-analysis. Mycoses 2001; 44:125-135. (Pubitemid 32641502)
77. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in nonneutropenic patients: A randomised noninferiority trial. Lancet 2005; 366:1435-1442. (Pubitemid 41483809)
78. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020-2029. (Pubitemid 35461658)
79. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: A phase III randomised double-blind trial. Lancet 2007; 369:1519-1527. (Pubitemid 46670281)
80. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472-2482. (Pubitemid 46919773)
81. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 2003; 36:1221-1228. (Pubitemid 36629929)
82. Khan FA, Slain D, Khakoo RA. Candida endophthalmitis: focus on current and future antifungal treatment options. Pharmacotherapy 2007; 27:1711-1721. (Pubitemid 350234318)
83. Breit SM, Hariprasad SM, Mieler WF, et al. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005; 139:135-140. (Pubitemid 40094850)
84. Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004; 122:42-47. (Pubitemid 38063603)
85. Lau D, Leung L, Ferdinands M, et al. Penetration of 1% voriconazole eye drops into human vitreous humour: A prospective, open-label study. Clin Experiment Ophthalmol 2009; 37:197-200.
86. Vemulakonda GA, Hariprasad SM, Mieler WF, et al. Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans. Arch Ophthalmol 2008; 126:18-22.
87. Biju R, Sushil D, Georgy NK. Successful management of presumed Candida endogenous endophthalmitis with oral voriconazole. Indian J Ophthalmol 2009; 57:306-308.
88. JangGJ, Kim KS, Shin WS, Lee WK. Treatment of candida chorioretinitis with voriconazole. Korean J Ophthalmol 2005; 19:73-76.
89. Lin RC, Sanduja N, Hariprasad SM. Successful treatment of postoperative fungal endophthalmitis using intravitreal and intracameral voriconazole. J Ocul Pharmacol Ther 2008; 24:245-248. (Pubitemid 351450477)
90. Varma D, Thaker HR, Moss PJ, et al. Use of voriconazole in candida retinitis. Eye 2005; 19:484-485.
91. Sen P, Gopal L, Sen PR. Intravitreal voriconazole for drug-resistant fungal endophthalmitis: case series. Retina 2006; 26:935-939. (Pubitemid 44547449)
92. Reis A, Sundmacher R, Tintelnot K, et al. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol 2000; 84:932-933. (Pubitemid 30599111)
93. Durand ML, Kim IK, D'Amico DJ, et al. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol 2005; 140:552-554. (Pubitemid 41224861)
94. Zarkovic A, Guest S. Scedosporiumapiospermum traumatic endophthalmitis successfully treated with voriconazole. Int Ophthalmol 2007; 27:391-394. (Pubitemid 350090647)
95. Vela JI, Diaz-Cascajosa J, Sanchez F, et al. Management of endogenous cryptococcal endophthalmitis with voriconazole. Can J Ophthalmol 2009; 44:e61-e62.
96. Sponsel WE, Graybill JR, Nevarez HL, Dang D. Ocular and systemic posaconazole (SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br J Ophthalmol 2002; 86:829-830. (Pubitemid 34713177)
97. Tu EY, McCartney DL, Beatty RF, et al. Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). Am J Ophthalmol 2007; 143:222-227.
98. Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 2005; 41:e27-e28.
99. Goldblum D, Fausch K, Frueh BE, et al. Ocular penetration of caspofungin in a rabbit uveitis model. Graefes Arch Clin Exp Ophthalmol 2007; 245:825-833. (Pubitemid 46805613)
100. Groll AH, Mickiene D, Petraitis V, et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 2001; 45: 3322-3327. (Pubitemid 33107841)
101. Groll AH, Mickiene D, Petraitiene R, et al. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrob Agents Chemother 2001; 45:2845-2855. (Pubitemid 32906681)
102. Sarria JC, Bradley JC, Habash R, et al. Candida glabrata endophthalmitis treated successfully with caspofungin. Clin Infect Dis 2005; 40:e46-e48.
103. Steinbach WJ, Perfect JR, Cabell CH, et al. A meta-analysis of medical versus surgical therapy for Candida endocarditis. J Infect 2005; 51:230-247. (Pubitemid 41554832)
104. Baddley JW, Benjamin DK Jr, Patel M, et al. Candida infective endocarditis. Eur J Clin Microbiol Infect Dis 2008; 27:519-529.
105. Cornely OA, Lasso M, Betts R, et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother 2007; 60:363-369. (Pubitemid 47243887)
106. Rajendram R, Alp NJ, Mitchell AR, et al. Candida prosthetic valve endocarditis cured by caspofungin therapy without valve replacement. Clin Infect Dis 2005; 40:e72-e74.
107. Talarmin JP, Boutoille D, Tattevin P, et al. Candida endocarditis: role of newantifungal agents. Mycoses 2009; 52:60-66.
108. Bacak V, Biocina B, Starcevic B, et al. Candida albicans endocarditis treatment with caspofungin in an HIV-infected patient: case report andreview of literature. J Infect 2006; 53:e11-e14. (Pubitemid 43960452)
109. Lye DC, Hughes A, O'Brien D, Athan E. Candida glabrata prosthetic valveendocarditis treated successfully with fluconazole plus caspofungin without surgery: A case report and literature review. Eur J Clin Microbiol Infect Dis 2005; 24:753-755. (Pubitemid 41752073)
110. Lopez-Ciudad V, Castro-Orjales MJ, Leon C, et al. Successful treatment ofCandida parapsilosis mural endocarditis with combined caspofungin and voriconazole. BMC Infect Dis 2006; 6:73.
111. Jimenez-Exposito MJ, Torres G, Baraldes A, et al. Native valve endocarditis due to Candida glabrata treated without valvular replacement: A potential rolefor caspofungin in the induction and maintenance treatment. Clin Infect Dis 2004; 39:e70-e73.
112. Malani AN, Kauffman CA. Changing epidemiology of rare mould infections: implications for therapy. Drugs 2007; 67:1803-1812. (Pubitemid 47347394)
113. Munoz P, Guinea J, Bouza E. Treatment options in emerging mold infections. Curr Fungal Infect Rep 2008; 2:74-80.
114. Naggie S, Perfect JR. Molds: hyalohyphomycosis, phaeohyphomycosis, and zygomycosis. Clin Chest Med 2009; 30:337-353; vii-viii.
115. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-415. (Pubitemid 34851833)
116. Becker MJ, Lugtenburg EJ, Cornelissen JJ, et al. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003; 121:448-457. (Pubitemid 36628336)
117. Musher B, Fredricks D, Leisenring W, et al. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004; 42:5517-5522. (Pubitemid 39664330)
118. Meersseman W, Lagrou K, Maertens J, et al. Galactomannan in bronchoalveolar lavage fluid: A tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008; 177:27-34.
119. Woods G, Miceli MH, Grazziutti ML, et al. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: A study of 56 patients with hematologic cancer. Cancer 2007; 110:830-834. (Pubitemid 47257661)
120. Miceli MH, Grazziutti ML, Woods G, et al. Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 2008; 46:1412-1422. (Pubitemid 351589942)
121. Miceli MH, Maertens J, Buve K, et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer 2007; 110:112-120. (Pubitemid 46986424)
122. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: A prospective, multicenter, observational study. Transplantation 2006; 81:320-326. (Pubitemid 43255714)
123. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39:797-802. (Pubitemid 39244292)
124. Pappas PG. Opportunistic fungi: A view to the future. Am J Med Sci 2010; 340:253-257.
125. Rogers TR. Treatment of zygomycosis: current and new options. J Antimicrob Chemother 2008; 61 (Suppl 1):i35-i40.
126. Alastruey-Izquierdo A, Castelli MV, Cuesta I, et al. In vitro activity of antifungals against Zygomycetes. Clin Microbiol Infect 2009; 15 (Suppl 5):71-76.
127. Ibrahim AS, Gebremariam T, Fu Y, et al. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother 2008; 52:1556-1558. (Pubitemid 351522035)
128. Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008; 47:364-371. (Pubitemid 352009357)
129. Spreghini E, Orlando F, Giannini D, Barchiesi F. In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility. J Antimicrob Chemother 2010; 65:2158-2163.
130. Sun QN, Fothergill AW, McCarthy DI, et al. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46:1581-1582. (Pubitemid 34415351)
131. Sun QN, Najvar LK, Bocanegra R, et al. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 2002; 46:2310-2312. (Pubitemid 34665939)
132. Rodriguez MM, Serena C, Marine M, et al. Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae. Antimicrob Agents Chemother 2008; 52: 3786-3788.
133. Alexander BD, Perfect JR, Daly JS, et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation 2008; 86:791-796.
134. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50:126-133. (Pubitemid 43042912)
135. van Burik JA, Hare RS, Solomon HF, et al. Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases. Clin Infect Dis 2006; 42:e61-e65.
136. Peel T, Daffy J, Thursky K, et al. Posaconazole as first line treatment for disseminated zygomycosis. Mycoses 2008; 51:542-545.
137. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20:695-704. (Pubitemid 47623773)
138. Lortholary O, Obenga G, Biswas P, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 2010; 54:4446-4450.
139. Espinel-Ingroff A, Johnson E, Hockey H, Troke P. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole phase III clinical studies. J Antimicrob Chemother 2008; 61:616-620. (Pubitemid 351321136)
140. Lalitha P, Shapiro BL, Srinivasan M, et al. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis. Arch Ophthalmol 2007; 125:789-793. (Pubitemid 46919740)
141. Stanzani M, Tumietto F, Vianelli N, Baccarani M. Update on the treatment of disseminated fusariosis: focus on voriconazole. Ther Clin Risk Manag 2007; 3:1165-1173.
142. Ruiz-Cendoya M, Marine M, Guarro J. Combined therapy in treatment of murine infection by Fusarium solani. J Antimicrob Chemother 2008; 62:543-546.
143. Ruiz-Cendoya M, Marine M, Rodriguez MM, Guarro J. Interactions between triazoles and amphotericin B in treatment of disseminated murine infection by Fusarium oxysporum. Antimicrob Agents Chemother 2009; 53:1705-1708.
144. Consigny S, Dhedin N, Datry A, et al. Successsful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient. Clin Infect Dis 2003; 37:311-313. (Pubitemid 36930364)
145. Gupta S, Almyroudis NG, Battiwalla M, et al. Successful treatment of disseminated fusariosis with posaconazole during neutropenia and subsequent allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2007; 9:156-160. (Pubitemid 46669084)
146. Sagnelli C, Fumagalli L, Prigitano A, et al. Successful voriconazole therapy of disseminated Fusarium verticillioides infection in an immunocompromised patient receiving chemotherapy. J Antimicrob Chemother 2006; 57:796-798.
147. Bigley VH, Duarte RF, Gosling RD, et al. Fusarium dimerum infection in a stem cell transplant recipient treated successfully with voriconazole. Bone Marrow Transplant 2004; 34:815-817. (Pubitemid 39467894)
148. Guimera-Martin-Neda F, Garcia-Bustinduy M, Noda-Cabrera A, et al. Cutaneous infection by Fusarium: successful treatment with oral voriconazole. Br J Dermatol 2004; 150:777-778. (Pubitemid 38586239)
149. Gorman SR, Magiorakos AP, Zimmerman SK, Craven DE. Fusarium oxysporum pneumonia in an immunocompetent host. South Med J 2006; 99:613-616. (Pubitemid 43999925)
150. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122-1131. (Pubitemid 36549632)
151. Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005; 40 (Suppl 6):S401-S408. (Pubitemid 40563297)
152. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42:1398-1403.
153. Spriet I, Delaere L, Lagrou K, et al. Intraocular penetration of voriconazole and caspofungin in a patient with fungal endophthalmitis. J Antimicrob Chemother 2009; 64:877-878.
154. Ho DY, Lee JD, Rosso F, Montoya JG. Treating disseminated fusariosis: Amphotericin B, voriconazole or both? Mycoses 2007; 50:227-231. (Pubitemid 46683972)
155. Stanzani M, Vianelli N, Bandini G, et al. Successful treatment of disseminated Fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B. J Infect 2006; 53:e243-e246. (Pubitemid 44688987)
156. Lamaris GA, Chamilos G, Lewis RE, et al. Scedosporium infection in a tertiary care cancer center: A review of 25 cases from 1989-2006. Clin Infect Dis 2006; 43:1580-1584. (Pubitemid 44901901)
157. Husain S, Munoz P, Forrest G, et al. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis 2005; 40:89-99. (Pubitemid 40053464)
158. Rodriguez-Tudela JL, Berenguer J, Guarro J, et al. Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. Med Mycol 2009; 47:359-370.
159. Heath CH, Slavin MA, Sorrell TC, et al. Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clin Microbiol Infect 2009; 15:689-693.
160. Meletiadis J, Meis JF, Mouton JW, et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002; 46:62-68. (Pubitemid 34031603)
161. Wiederhold NP, Lewis RE. Antifungal activity against Scedosporium species and novel assays to assess antifungal pharmacodynamics against filamentousfungi. Med Mycol 2009; 47:422-432.
162. Sarva ST, Manjunath SK, Baldwin HS, et al. Lung scedosporiosis in human immunodeficiency virus/acquired immunodeficiency syndrome. Am J Med Sci 2010; 339:300-303.
163. Chakraborty A, Workman MR, Bullock PR. Scedosporium apiospermum brain abscess treated with surgery and voriconazole. Case report. J Neurosurg 2005; 103:83-87. (Pubitemid 44954954)
164. Leechawengwongs M, Milindankura S, Liengudom A, et al. Multiple Scedosporium apiospermum brain abscesses after near-drowning successfully treated with surgery and long-term voriconazole: A case report. Mycoses 2007; 50:512-516. (Pubitemid 47609823)
165. Munoz P, Marin M, Tornero P, et al. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy. Clin Infect Dis 2000; 31:1499-1501.
166. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21:240-248. (Pubitemid 34214142)
167. Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008; 52:1743-1750. (Pubitemid 351614668)
168. Mellinghoff IK, Winston DJ, Mukwaya G, Schiller GJ. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin Infect Dis 2002; 34:1648-1650. (Pubitemid 34615452)
169. Meletiadis J, Mouton JW,Meis JF, Verweij PE. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother 2003; 47:106-117. (Pubitemid 36070350)
170. Bhat SV, Paterson DL, Rinaldi MG, Veldkamp PJ. Scedosporium prolificans brain abscess in a patient with chronic granulomatous disease: successful combination therapy with voriconazole and terbinafine. Scand J Infect Dis 2007; 39:87-90. (Pubitemid 46277156)
171. Gosbell IB, Toumasatos V, Yong J, et al. Cure of orthopaedic infection with Scedosporium prolificans, using voriconazole plus terbinafine, without the need for radical surgery. Mycoses 2003; 46:233-236. (Pubitemid 36808246)
172. Howden BP, Slavin MA, Schwarer AP, Mijch AM. Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine. Eur J Clin Microbiol Infect Dis 2003; 22:111-113. (Pubitemid 36349974)
173. Li JY, Yong TY, Grove DI, Coates PT. Successful control of Scedosporiumprolificans septic arthritis and probable osteomyelitis without radical surgery in a long-term renal transplant recipient. Transpl Infect Dis 2008; 10:63-65. (Pubitemid 351171314)
174. Revankar SG. Phaeohyphomycosis. Infect Dis Clin North Am 2006; 20:609-620.
175. Ben-Ami R, Lewis RE, Raad II, Kontoyiannis DP. Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis 2009; 48:1033-1041.
176. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39:954-958. (Pubitemid 32209706)
177. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determinedby NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20:121-136. (Pubitemid 38724618)
178. Koo S, Klompas M, Marty FM. Fonsecaea monophora cerebral phaeohyphomycosis: case report of successful surgical excision and voriconazole treatment and review. Med Mycol 2010; 48:769-774.
179. Larsen CG, Arendrup MC, Krarup E, et al. Subcutaneous phaeohyphomycosis in a renal transplant recipient successfully treated with voriconazole. Acta Derm Venereol 2009; 89:657-658.
180. Al-Abdely HM, Alkhunaizi AM, Al-Tawfiq JA, et al. Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole. Med Mycol 2005; 43:91-95. (Pubitemid 40192606)
181. Graybill JR, Najvar LK, Johnson E, et al. Posaconazole therapy of disseminated phaeohyphomycosis in a murine model. Antimicrob Agents Chemother 2004; 48:2288-2291. (Pubitemid 38691633)
182. Rivard RG, McCall S, Griffith ME, et al. Efficacy of caspofungin and posaconazole in a murine model of disseminated Exophiala infection. Med Mycol 2007; 45:685-689. (Pubitemid 350153960)
183. Negroni R, Helou SH, Petri N, et al. Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera. Clin Infect Dis 2004; 38:e15-e20.
184. Proia LA, Trenholme GM. Chronic refractory phaeohyphomycosis: successful treatment with posaconazole. Mycoses 2006; 49:519-522. (Pubitemid 44511107)
185. Lewis RE. Antifungal drug monitoring. Curr Fungal Infect Rep 2010; 4:158-167.
186. Wilson DT, Drew RH, Perfect JR. Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: An update. Mycopathologia 2009; 168:313-327.
187. Pascual A, Calandra T, Bolay S, et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46:201-211. (Pubitemid 351269158)
188. Eiden C, Peyriere H, Cociglio M, et al. Adverse effects of voriconazole: Analysis of the French Pharmacovigilance Database. Ann Pharmacother 2007; 41:755-763. (Pubitemid 46752655)
189. Vadnerkar A, Nguyen MH, Mitsani D, et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant 2010; 29:1240-1244.
190. Miller DD, Cowen EW, Nguyen JC, et al. Melanoma associated with longterm voriconazole therapy: A new manifestation of chronic photosensitivity. Arch Dermatol 2010; 146:300-304.
191. Cowen LE, Singh SD, Kohler JR, et al. Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc Natl Acad Sci U S A 2009; 106:2818-2823.
192. Blankenship JR, Steinbach WJ, Perfect JR, Heitman J. Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. Curr Opin Investig Drugs 2003; 4:192-199. (Pubitemid 36383016)
193. Pfaller MA, Messer SA, Georgopapadakou N, et al. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J Clin Microbiol 2009; 47:3797-3804.
194. Pfaller MA, Diekema DJ, Gibbs DL, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: A 10.5-year analysis of susceptibilities of Candida Species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J Clin Microbiol 2010;48:1366-1377.
195. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010; 36:1-53.
196. Pfaller MA, Diekema DJ, Gibbs DL, et al. Geographic variation in the frequency of isolation and fluconazole and voriconazole susceptibilities ofCandida glabrata: An assessment from the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 2010; 67:162-171.
197. Chamilos G, Kontoyiannis DP. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resist Updat 2005; 8:344-358. (Pubitemid 43358058)
198. Girmenia C. New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs 2009; 18:1279-1295.
199. ThompsonGR3rd, Wiederhold NP. Isavuconazole: A comprehensive review of spectrum of activity of a new triazole. Mycopathologia 2010; 170:291-313.